epiglucan and Head-and-Neck-Neoplasms

epiglucan has been researched along with Head-and-Neck-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for epiglucan and Head-and-Neck-Neoplasms

ArticleYear
Metastasis and immunosuppression promoted by mtDNA and PD-L1 in extracellular vesicles are reversed by WGP β-glucan in oral squamous cell carcinoma.
    Cancer science, 2023, Volume: 114, Issue:10

    The suppressive regulatory T cells (Treg) are frequently upregulated in cancer patients. This study aims to demonstrate the hypothesis that arecoline could induce the secretion of mitochondrial (mt) DNA D-loop and programmed cell death-ligand 1 (PD-L1) in extracellular vesicles (EVs), and attenuate T-cell immunity by upregulated Treg cell numbers. However, the immunosuppression could be reversed by whole glucan particle (WGP) β-glucan in oral squamous cell (OSCC) patients. Arecoline-induced reactive oxygen specimen (ROS) production and cytosolic mtDNA D-loop were analyzed in OSCC cell lines. mtDNA D-loop, PD-L1, IFN-γ, and Treg cells were also identified for the surgical specimens and sera of 60 OSCC patients. We demonstrated that higher mtDNA D-loop, PD-L1, and Treg cell numbers were significantly correlated with larger tumor size, nodal metastasis, advanced clinical stage, and areca quid chewing. Furthermore, multivariate analysis confirmed that higher mtDNA D-loop levels and Treg cell numbers were unfavorable independent factors for survival. Arecoline significantly induced cytosolic mtDNA D-loop leakage and PD-L1 expression, which were packaged by EVs to promote immunosuppressive Treg cell numbers. However, WGP β-glucan could elevate CD4

    Topics: Arecoline; B7-H1 Antigen; beta-Glucans; Carcinoma, Squamous Cell; DNA, Mitochondrial; Extracellular Vesicles; Glucans; Head and Neck Neoplasms; Humans; Immunosuppression Therapy; Mouth Neoplasms; Squamous Cell Carcinoma of Head and Neck

2023